Bladder Cancer

Mechanistically, rs7087341 A allele decreased AKR1C2 expression, which was highly expressed in bladder tumors that enhanced metabolism of tobacco carcinogens, and thereby increased DNA adducts and reactive oxygen species formation during bladder tumorigenesis. These findings provided new insights into the genetic mechanisms underlying bladder cancer.

Expression of PD-L1 was detected in a cohort of NCC patients, although the PD-L1 positivity rate was lower than that in BC. Our results demonstrate that the degree of PD-L1 expression in bladder tissue is associated with the presence of viral infections and with the degree of inflammatory infiltration of the bladder wall in both NCC and BC.

We have effectively discerned pivotal genes from the endothelial cell perspective and constructed an EPI for BC patients, thereby offering promising prospects for precision medicine.

The TSRP is composed of: i) Recognition unit could specifically target and inhibit the biological function of FGFR-1; ii) Transformable unit could self-assembly and trigger nanofibers formation; iii) Reactive unit could specifically cleaved by MMP-2/9 in tumor micro-environment; iv) Immune unit, stimulate the release of immune cells when LTX-315 (Immune-associated oncolytic peptide) exposed...All above processes together contribute to the increasing survival rate of tumor-bearing mice by nearly 4-folds. This work presented a unique design for the biological application of one-step synergistic therapy of bladder cancer.

P3, N=250, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

P3, N=540, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting

It cannot be fully excluded that the strong statistical link between PD-L1 status and favorable histological tumor features as well as better prognosis could influence the outcome of studies evaluating CPIs in muscle-invasive urothelial carcinoma.

The differences in the expression of KIFC2 in the bladder cancer tissues (14 pairs) were statistically significant. The pan-cancer analysis in this study revealed the multifunctionality of KIFC2 in a variety of tumors, indicating a possible prognostic predictor and potential therapeutic target for tumors.

NECTIN4 amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.

However, the impact of SLC3A2 interference on cell proliferation and macrophage polarization was impeded by ferroptosis inhibitors. Interference with SLC3A2 inhibited the growth of BLCA cells and the polarization of tumor-associated macrophages by promoting ferroptosis in BLCA cells.

P=N/A, N=150, Terminated, Pfizer | Trial completion date: Oct 2023 --> Jun 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Jun 2023; The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.

P=N/A, N=77, Terminated, PPsanalytics | Recruiting --> Terminated; Lack of enrollment due to amended inclusion criteria

P3, N=1050, Recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2030 --> Sep 2029

P3, N=0, Withdrawn, Second Xiangya Hospital of Central South University | N=120 --> 0 | Recruiting --> Withdrawn

P=N/A, N=1200, Completed, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Other explanatory hypotheses include neoplastic stem cells, a genetic predisposition to malignancy, the use of immunosuppressive agents for the treatment for a first neoplasm, viral agents, and modulation of the B-cell system by monoclonal T-cell proliferation (1,5,6,9,10). Regular follow-up is mandatory for all patients with CTCL as well as MF, in order to identify the disease progression but for the timely detection of second malignancies.

OSNA can predict the occurrence of SLN metastasis accurately in CK19 positive cancers, especially in breast cancer, colorectal cancer, lung cancer, gastric cancer and endometrial cancer. Our study warrants future studies investigating the clinical application of OSNA in pancreatic, ovarian and bladder cancers.

We identified 7 lncrnas associated with aniline poisoning and established a novel risk model of lncrnas associated with aniline poisoning,which provides new insights for prognosis assessment and may guide the comprehensive treatment of male bladder cancer.

P=N/A, N=180, Recruiting, Dana-Farber Cancer Institute | Not yet recruiting --> Recruiting

It summarizes the therapeutics, mechanisms of action, research advances and challenges of targeting CD47. In addition, this paper provides an overview of the latest therapeutic options for targeting CD47, such as chimeric antigen receptor (CAR) T-cells, CAR macrophages and nanotechnology-based delivery systems, which are essential for future clinical research on targeting CD47.

P1/2, N=24, Not yet recruiting, RemeGen Co., Ltd.

P1, N=85, Completed, Pieris Pharmaceuticals, Inc. | Trial completion date: Oct 2021 --> Dec 2023 | Trial primary completion date: Oct 2021 --> Dec 2023

P4, N=100, Recruiting, Roswell Park Cancer Institute | Trial primary completion date: Sep 2024 --> Mar 2025

P1, N=41, Completed, Pieris Pharmaceuticals, Inc. | Active, not recruiting --> Completed | Phase classification: P1b --> P1

P3, N=800, Recruiting, Hoffmann-La Roche | N=520 --> 800

Our results, indicate, that comparing expression levels of these genes in cancer and cancer-free tissue could provide valuable data, as patients with pTa BC recurrence within up to 54 months of follow-up had a significantly higher RQ of TP53, GATA3, and FOXA1 when compared to pTa BC patients without recurrence (Tab. 2, Fig. 8, Ref. 54). Text in PDF www.elis.sk Keywords: bladder cancer, gene expression, recurrence, GATA3, FOXA1, TP53, BCL2.

PATIENT SUMMARY: We analyzed patient samples from two clinical trials (NRG/RTOG 0524 and 0712) of chemoradiation for muscle-invasive bladder cancer using a novel method to assess immune cells in the tumor microenvironment. Higher expression of genes associated with immune activation and high overall immune-cell content were associated with better disease-free survival and overall survival for patients treated with chemoradiation.

These controversial findings may be derived from cancer cell types, conditions, and ligands, since some ligands are independent of PPARγ activity. Therefore, this review discussed the dual role of PPARγ on tumor progression and immunotherapy.

P1, N=49, Completed, Roswell Park Cancer Institute | Recruiting --> Completed | N=100 --> 49

P3, N=13, Terminated, Bristol-Myers Squibb | Trial completion date: Oct 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Insufficient enrollment, inability to meet protocol objectives, and slow accrual.

In conclusion, BLCA-1 was a better biomarker than cystatin C and MTDH. Cystatin C, BLCA-1 and MTDH levels, can differentiate between benign bladder lesion and BC and correlated with tumor grades.especially with OL-HDF compared to HF-HD, with acceptable albumin loss in the dialysate.

The IC50 of cells to gemcitabine was determined using the CCK8 assay...Simultaneously, EGLN2-mediated degradation of HIF-1α was reduced. This ultimately led to elevated HIF-1α-mediated downstream gene expression, promoting increased glucose uptake and glycolysis, and ultimately resulting in heightened chemotherapy resistance and malignancy.

In conclusion, circKDM1A functions as a tumor suppressor in the malignant proliferation of BCa via the miR-889-3p/CPEB3/p53 axis. CircKDM1A may be a potential prognostic biomarker and therapeutic target of BCa.

P1, N=60, Recruiting, UroGen Pharma Ltd. | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P=N/A, N=250, Recruiting, Yonsei University

P=N/A, N=11, Terminated, Cedars-Sinai Medical Center | Active, not recruiting --> Terminated; Slow accrual

P=N/A, N=104, Completed, Sun Yat-sen University | Recruiting --> Completed

Treatment with si-m/hVDAC1-B encapsulated in PLGA-PEI nanoparticles that were administered intravesically directly to the bladder showed a decreased tumor area and less bladder morphology destruction and muscle invasion. Overall, the obtained results point to the potential of si-m/hVDAC1-B as a possible therapeutic tool for treating bladder cancer.

Immunotumoroid response to ICIs (nivolumab, pembrolizumab, and durvalumab) and chemotherapy (cisplatin, gemcitabine, and paclitaxel) was monitored in real-time with Cytotox Red staining in an Incucyte device, and the immunotumoroid response was compared to retrospective clinical drug responses. This model could enable valuable insights into the complex interactions between cancer cells, the immune system, and the microenvironment. This is a feasibility study on a small number of cases, and additional studies with larger case numbers are required including correlation with clinical response.

A bioinformatics analysis also identified a positive association between CHI3L1 expression and lymphangiogenesis or immunosuppression pathways. Our study established a clear association between stromal CHI3L1 expression and lymphatic metastasis, suggesting that stromal CHI3L1 expression is a potential prognostic marker for bladder cancer patients.

P=N/A, N=2000, Recruiting, M.D. Anderson Cancer Center | N=20000 --> 2000

P1, N=15, Recruiting, Ractigen Therapeutics. | Not yet recruiting --> Recruiting